Search

Your search keyword '"Pilar, Zamora"' showing total 348 results

Search Constraints

Start Over You searched for: Author "Pilar, Zamora" Remove constraint Author: "Pilar, Zamora"
348 results on '"Pilar, Zamora"'

Search Results

201. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium

202. Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers

203. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

204. CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients

205. A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC)

206. Selegiline (deprenyl) decreases calbindin-D28k expression in cortical neurons of rats socially deprived during the post-weaning period

207. Comparison of 6q25 Breast Cancer Hits from Asian and\ud European Genome Wide Association Studies in the\ud Breast Cancer Association Consortium (BCAC)

208. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium

209. Gene profiling in breast cancer: Time to move forward

210. Adjuvant hormonal therapy in perimenopausal patients

211. Reports of Oncological Societies

212. Angiogenesis as a therapeutic target in urothelial carcinoma

213. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

214. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.

215. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

216. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

217. Abstract P4-05-04: Proteomic patterns unravel a new luminal-A breast cancer molecular subgroup with prognostic value

218. Pregnancy in a breast cancer patient treated with a LHRH analogue at ablative doses

219. Palliative care is a key component of daily practice in oncology: descriptive study of hospitalisation events at an oncology treatment centre

220. Intra-abdominal desmoplastic small round cell tumour in a 39-year-old man

221. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies

222. Effects of neonatal maternal deprivation and postweaning environmental complexity on dendritic morphology of prefrontal pyramidal neurons in the rat

223. Cirrhosis-like radiological pattern in patients with breast cancer

224. Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma

225. Predictive factors of grade 3-5 toxicity in elderly cancer patients treated with chemotherapy: A prospective multicenter study (TEP study: Toxicity in Elderly Patient)

226. Neutrophil-lymphocite ratio in stage II-III testicular germ cell tumors before initiating chemotherapy: Correlation with survival

227. Abstract P2-01-29: Axillary involvement in lobular breast cancer

228. Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

229. Disruption of the actin network enhances MAP-2c and Fyn-induced process outgrowth

230. Doctors also suffer when giving bad news to cancer patients

231. Fyn phosphorylates human MAP-2c on tyrosine 67

232. The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations

233. Classification of anticancer drugs--a new system based on therapeutic targets

234. Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1

235. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

236. Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

237. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer (MBC) treated with bevacizumab and weekly paclitaxel (Bev-Pac)

238. Renal tolerance to cisplatin in patients 70 years and older

239. Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2

240. 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

241. Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

242. 11q13 is a susceptibility locus for hormone receptor positive breast cancer

243. 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

244. Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2

245. Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer

246. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study

247. The Long-HER study: Clinical and molecular analysis of advanced HER2+ breast cancer treated with trastuzumab and associated to long-term survival

249. Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastatic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study

250. Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

Catalog

Books, media, physical & digital resources